Colorectal Cancer (CRC) Not Yet Recruiting Phase 3 Trials for Fluorouracil (DB00544)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Not Yet Recruiting	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT07271355	Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial	Treatment	Bevacizumab (DB00112) Camptothecin (DB04690) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Levoleucovorin (DB11596) Mitomycin (DB00305)
NCT07729605	FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT07595276	Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07362836	Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Fruquintinib (DB11679) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06616259	First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study	Treatment	Capecitabine (DB01101) Cetuximab (DB00002) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06899477	Pre-Operative Treatment in REseCTable COlon CanceR	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05948072	Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05427669	Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)	Treatment	Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)